Status:
NOT_YET_RECRUITING
The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM
Lead Sponsor:
Southern Medical University, China
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The study of investigators indicated that TMZ can up-regulate dopamine D2 receptor (DRD2) expression, and mediates Ferroptosis inhibition and chemoresistance of GBM. The clinical data also proved that...
Eligibility Criteria
Inclusion
- Adult patients
- Primary GBM underwent surgery and TMZ chemoradiotherapy, and MRI confirmed the tumor recurrence
- Without severe cardiac diseases
Exclusion
- Child patients (\<18 years)
- Recurrence tumors grow fast, which needs surgery removal
- H3K27M midline glioblastoma
- Suffered with severe cardiac diseases
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06218524
Start Date
December 1 2024
End Date
July 31 2028
Last Update
January 23 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.